Malignant hyperthermia

Best Practice and Research: Clinical Anaesthesiology

Volumn 17, Issue 4, 2003, Pages 519-533

  Ali, Syed Z ^a   Taguchi, Akiko ^b   Rosenberg, Henry ^c,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAINT BARNABAS MEDICAL CENTER   (United States)

^d Malignant Hyperther Assoc of US   (United States)

Author keywords

Caffeine; Calcium ion; Dantrolene; Halothane; In vitro contracture test; Life threatening condition; Malignant hyperthermia; Myopathy; Rhabdomyolysis; Ryanodine receptor

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; BICARBONATE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; CHLOROCRESOL; DANTROLENE; DIAZEPAM; DIURETIC AGENT; FUROSEMIDE; GLUCOSE; HALOPERIDOL; HALOTHANE; INHALATION ANESTHETIC AGENT; INOSITOL 1,4,5 TRISPHOSPHATE; INSULIN; LIDOCAINE; MANNITOL; MUSCLE RELAXANT AGENT; MYOSIN; NEUROLEPTIC AGENT; OPIATE DERIVATIVE; PETHIDINE; PHENOBARBITAL; PROPRANOLOL; RYANODINE; RYANODINE RECEPTOR; SEDATIVE AGENT; SUXAMETHONIUM; UNINDEXED DRUG; CENTRAL MUSCLE RELAXANT;

ARTIFICIAL VENTILATION; BECKER MUSCULAR DYSTROPHY; BIOCHEMISTRY; CLINICAL FEATURE; CLINICAL TRIAL; COOLING; CYTOPLASM; DEPRESSION; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG HALF LIFE; DUCHENNE MUSCULAR DYSTROPHY; ELECTROLYTE DISTURBANCE; END TIDAL CARBON DIOXIDE TENSION; EXERCISE; GENE MUTATION; HEART ARREST; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEAT STROKE; HUMAN; HYDRATION; HYPERKALEMIA; HYPERMETABOLISM; HYPERTHERMIA; HYPOKALEMIA; MALIGNANT HYPERTHERMIA; METABOLIC ACIDOSIS; MORTALITY; MUSCLE RIGIDITY; MYOGLOBINURIA; MYOPATHY; MYOTONIA; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; OXYGENATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SARCOPLASMIC RETICULUM; TACHYCARDIA; ANESTHESIA; DIFFERENTIAL DIAGNOSIS; GENETICS; PATIENT EDUCATION;

ANESTHESIA; ANESTHETICS, INHALATION; DANTROLENE; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE RELAXANTS, CENTRAL; PATIENT EDUCATION;

EID: 1542753655     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2003.09.012     Document Type: Review

References (76)

1. Jurkat-Rott K. McCarthy T. Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia Muscle and Nerve 23 2000 4-17
2. 2+ ions from human malignant hyperthermia-susceptible sarcoplasmic reticulum Biochemical Pharmacology 61 2001 1479-1485
3. McCarthy T.V. Quane K.A. Lynch P.J. Ryanodine receptor mutations in malignant hyperthermia and central core disease Human Mutation 15 2000 410-417
4. Melzer W. Dietze B. Malignant hyperthermia and excitation-contraction coupling Acta Anaesthesiologica Scandinavica 171 2001 367-378
5. Denborough M.A. Anaesthetic deaths in a family (letter) Lancet 2 1960 45
6. Denborough M.A. et al. Anaesthetic deaths in a family British Journal of Anaesthesia 34 1962 395
7. Isaacs H. Barlow M.B. Malignant hyperpyrexia during anaesthesia: possible association with subclinical myopathy British Medical Journal 1 1970 275-277
8. Kalow W. Britt B.A. Terreau M.E. et al. Metabolic error of muscle metabolism after recovery from malignant hyperthermia Lancet 2 7679 1970 895-898
9. Ellis F.R. Harriman D.G. Keaney N.P. et al. Halothane-induced muscle contracture as a cause of hyperpyrexia British Journal of Anaesthesia 43 7 1971 721-724
10. Harrison G.G. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium British Journal of Anaesthesia 47 1975 62-65
11. Austin K.L. Denborough M.A. Drug treatment of malignant hyperpyrexia Anaesthesia and Intensive Care 5 1977 207-213
12. Kolb M.E. Horne M.L. Martz R. Dantrolene in human malignant hyperthermia Anesthesiology 56 1982 254-262
13. 2+ release channels American Journal of Medicine 104 1998 470-486
14. Abraham R.B. Adnet P. Glauber V. et al. Malignant hyperthermia Postgraduate Medical Journal 74 1998 11-17
15. Hogan K. The anesthetic myopathies and malignant hyperthermias Current Opinion in Neurology 11 1998 469-476
16. Monnier N. Krivosic-Horber R. Payen J.F. et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility Anesthesiology 97 5 2002 1067-1074
17. Britt B.A. Endrenyi L. Peters P.L. et al. Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations Canadian Anaesthetists' Society Journal 23 3 1976 263-284
18. Strazis K.P. Fox A.W. Malignant hyperthermia: a review of published cases Anesthesia and Analgesia 77 1993 297-304
19. MacLennan D.H. Phillips M.S. The role of the skeletal muscle ryanodine receptor (RYR1) gene in malignant hyperthermia and central core disease Society of General Physiologists Series 50 1995 89-100
20. Sewall K. Flowerdew R.M. Bromberger P. Severe muscular rigidity at birth: malignant hyperthermia syndrome? Canadian Anaesthetists' Society Journal 27 1980 279-282
21. Faust D.K. Gergis S.D. Sokoll M.D. Management of suspected malignant hyperpyrexia in an infant Anesthesia and Analgesia 58 1979 33-35
22. Dempsey W.C. Mayhew J.F. Metz P.S. et al. Malignant hyperthermia during repair of a cleft lip in a 6-month-old infant, with survival Annals of Plastic Surgery 1 3 1978 315-318
23. Morison D.H. Placental transfer of dantrolene (letter) Anesthesiology 59 1983 265
24. MacLennan D.H. Duff C. Zorzato F. et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia Nature 343 6258 1990 559-561
25. McCarthy T.V. Healy J.M. Heffron J.J. et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2 Nature 343 6258 1990 562-564
26. Ueda I. Shinoda F. Kamaya H. et al. Malignant hyperthermia and calcium-induced heat production Canadian Journal of Anaesthesia 41 5 Pt 1 1994 440-445
27. Struk A. Lehmann-Horn F. Melzer W. Voltage-dependent calcium release in human malignant hyperthermia muscle fibers Biophysical Journal 75 1998 2402-2410
28. 2+ release from sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia. The effects of halothane and dantrolene FEBS Letters 161 1983 103-107
29. 2+ regulation defects Physiological Reviews 76 1996 537-592
30. Gronert G.A. Theye R.A. Halothane-induced porcine malignant hyperthermia: metabolic and hemodynamic changes Anesthesiology 44 1976 36-43
31. Vilven J. Coronado R. Opening of dihydropyridine calcium channels in skeletal muscle membranes by inositol trisphosphate Nature 336 1988 587-589
32. 2+ release Science 265 1994 813-815
33. Wappler F. Scholz J. Kochling A. et al. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia British Journal of Anaesthesia 78 5 1997 541-547
34. Lopez J.R. Perez C. Linares N. et al. Hypersensitive response of malignant hyperthermia-susceptible skeletal muscle to inositol 1,4,5-triphosphate induced release of calcium Naunyn-Schmiedeberg's Archives of Pharmacology 352 4 1995 442-446
35. Scholz J. Steinfath M. Roewer N. et al. Biochemical changes in malignant hyperthermia susceptible swine: cyclic AMP, inositol phosphates, alpha 1, beta 1- and beta 2-adrenoceptors in skeletal and cardiac muscle Acta Anaesthesiologica Scandinavica 37 1993 575-583
36. Gerdes C. Richter A. Annies R. et al. Increase of serotonin in plasma during onset of halothane-induced malignant hyperthermia in pigs European Journal of Pharmacology 220 1 1992 91-94
37. Loscher W. Witte U. Fredow G. et al. Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia Naunyn-Schmiedeberg's Archives of Pharmacology 341 6 1990 483-493
38. Wappler F. Roewer N. Kochling A. et al. Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients Anesthesiology 84 1996 1280-1287
39. Wappler F. Scholz J. von Richthofen V. et al. Attenuation of serotonin-induced contractures in skeletal muscle from malignant hyperthermia-susceptible patients with dantrolene Acta Anaesthesiologica Scandinavica 41 10 1997 1312-1318
40. Wappler F. Malignant hyperthermia European Journal of Anaesthesiology 18 2001 632-652
41. Allen G.C. Larach M.G. Kunselman A.R. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS Anesthesiology 88 1998 579-588
42. Hoenemann C.W. Halene-Holtgraeve T.B. Booke M. et al. Delayed onset of malignant hyperthermia in desflurane anesthesia Anesthesia and Analgesia 96 2003 165-167
43. Heffron J.J. Malignant hyperthermia: biochemical aspects of the acute episode British Journal of Anaesthesia 60 1988 274-278
44. Roewer N. Dziadzka A. Greim C.A. et al. Cardiovascular and metabolic responses to anesthetic-induced malignant hyperthermia in swine Anesthesiology 83 1 1995 141-159
45. Britt B.A. Malignant hyperthermia: a review Handbook of Experimental Pharmacology 60 1982 547-615
46. Habre W. Sims C. Masseter spasm and elevated creatine kinase after intravenous induction in a child Anaesthesia and Intensive Care 24 1996 496-499
47. O'Flynn R.P. Shutack J.G. Rosenberg H. et al. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis Anesthesiology 80 6 1994 1228-1233
48. Ramirez J.A. Cheetham E.D. Laurence A.S. et al. Suxamethonium, masseter spasm and later malignant hyperthermia Anaesthesia 53 11 1998 1111-1116
49. Sessler D.I. Malignant hyperthermia Acta Anaesthesiologica Scandinavica 109 1996 25-30
50. Iaizzo P.A. Kehler C.H. Zink R.S. et al. Thermal response in acute porcine malignant hyperthermia Anesthesia and Analgesia 82 4 1996 782-789
51. Kozak-Ribbens G. Bendahan D. Rodet L. et al. Metabolic events with spontaneous malignant hyperthermia crisis in an anaesthetized pig Canadian Journal of Anaesthesia 44 7 1997 757-764
52. Nelson T.E. Porcine malignant hyperthermia: critical temperatures for in vivo and in vitro responses Anesthesiology 73 1990 449-454
53. Gronert G.A. Milde J.H. Theye R.A. Porcine malignant hyperthermia induced by halothane and succinylcholine: failure of treatment with procaine or procainamide Anesthesiology 44 1976 124-132
54. Gronert G.A. Theye R.A. Milde J.H. et al. Catecholamine stimulation of myocardial oxygen consumption in porcine malignant hyperthermia Anesthesiology 49 1978 330-337
55. Tobin J.R. Jason D.R. Challa V.R. et al. Malignant hyperthermia and apparent heat stroke Jama 286 2 2001 168-169
56. McGugan E.A. Hyperpyrexia in the emergency department Emergency Medicine (Fremantle, W.A.) 13 2001 116-120
57. Larach M.G. Rosenberg H. Gronert G.A. et al. Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies Clinical Pediatrics (Philadelphia) 36 1 1997 9-16
58. Plattner O. Kurz A. Sessler D.I. et al. Efficacy of intraoperative cooling methods Anesthesiology 87 5 1997 1089-1095
59. Ellis K.O. Bryant S.H. Excitation-contraction uncoupling in skeletal muscle by dantrolene sodium Naunyn-Schmiedeberg's Archives of Pharmacology 274 1972 107-109
60. Ward A. Chaffman M.O. Sorkin E.M. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity Drugs 32 1986 130-168
61. Flewellen E.H. Nelson T.E. Dantrolene dose response in malignant hyperthermia-susceptible (MHS) swine: method to obtain prophylaxis and therapeusis Anesthesiology 52 1980 303-319
62. Flewellen E.H. Nelson T.E. Jones W.P. et al. Dantrolene dose response in awake man: implications for management of malignant hyperthermia Anesthesiology 59 4 1983 275-280
63. Hall G.M. Lunke J.N. Lovall R. et al. Porcine malignant hyperthermia. VII: Hepatic metabolism British Journal of Anaesthesia 52 1980 11-17
64. Putney J.W. Biancri C.P. Site of action of dantrolene in frog sartorius muscle Journal of Pharmacology and Experimental Therapeutics 189 1974 202-212
65. Kurihara T. Brooks J.E. Excitation-contraction uncoupling. The effect of hyperosomolar glycerol solution and antrolene sodium on mammalian muscle in vitro Archives of Neurology 32 1975 92-97
66. van Winkle W.B. Calcium release from skeletal muscle sarcoplasmic reticulum: site of action of dantrolene sodium Science 193 1976 1130-1131
67. Green R.A. Mitchell G. Heffron J.J. Effects of temperature, adenosine triphosphate and magnesium concentrations on the contraction of actomyosin isolated from halothane-sensitive and -insensitive German Landrace pigs British Journal of Anaesthesia 52 1980 319-323
68. Ryan J.F. Lopez J.R. Sanchez V.B. et al. Myoplasmic calcium changes precede metabolic and clinical signs of porcine malignant hyperthermia Anesthesia and Analgesia 79 5 1994 1007-1011
69. Ording H. Brancadoro V. Cozzolino S. et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group Acta Anaesthesiologica Scandinavica 41 8 1997 955-966
70. Hopkins P.M. Hartung E. Wappler F. Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. The European Malignant Hyperthermia Group British Journal of Anaesthesia 80 1998 389-394
71. Rosenberg H. Antognini J.F. Muldoon S. Testing for malignant hyperthermia Anesthesiology 96 2002 232-237
72. Anetseder M. Hager M. Muller C.R. et al. Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test Lancet 359 9317 2002 1579-1580
73. Urwyler A. Deufel T. McCarthy T. et al. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia British Journal of Anaesthesia 86 2 2001 283-287
74. Hackl W. Mauritz W. Schemper M. et al. Prediction of malignant hyperthermia susceptibility: statistical evaluation of clinical signs British Journal of Anaesthesia 64 4 1990 425-429
75. Rosenberg H. Fletcher J.E. Masseter muscle rigidity and malignant hyperthermia susceptibility Anesthesia and Analgesia 65 1986 161-164
76. Halsall P.J. Cain P.A. Ellis F.R. Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized British Journal of Anaesthesia 51 1979 949-954